<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495014</url>
  </required_header>
  <id_info>
    <org_study_id>DIX109981</org_study_id>
    <nct_id>NCT00495014</nct_id>
  </id_info>
  <brief_title>Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects</brief_title>
  <official_title>A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study represents the second Phase 1 study with GSK376501 and the goal is to further
      evaluate its safety and tolerability. The way the human body processes GSK376501 will also be
      determined.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose</measure>
    <time_frame>following each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GSK376501 following 1 day (Part A) or 14 days (Part B) of dosing</measure>
    <time_frame>following 1 day (Part A) or 14 days (Part B) of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK376501 plasma levels to derive pharmacokinetic parameters following single and repeat doses for 14 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard markers that may serve as possible surrogates of volume expansions with GSK376501.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight following 14 days of repeat dosing with GSK376501.</measure>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK376501</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <other_name>GSK376501</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is healthy and overweight/obese, defined as having a body mass index
             greater than 25 but less than 35kg/m2, inclusive.

          -  The subject is an adult male or a female of non-childbearing potential between the age
             of 18 and 65 years, inclusive, at the time of signing informed consent.

          -  The subject and their partner are willing to use double-barrier method of
             contraception from the first day of study drug administration until 5 half-lives of
             the drug have elapsed following the last day of study drug administration.

          -  The subject demonstrates an ECG with values within ranges specified in the protocol at
             screening or baseline.

          -  The subject is capable of giving written informed consent, which includes the ability
             to read, comprehend and comply with the protocol requirements and restrictions as
             described in the consent form.

        Exclusion Criteria:

          -  Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any
             medication that is chemically related to the study drug or a history of drug or other
             allergy that, in the opinion of the physician responsible, contraindicates their
             participation in the study.

          -  Has a known allergy to any of the tablet formulation excipients of GSK376501 or
             pioglitazone (as applicable).

          -  Has sensitivity to heparin or history of heparin-induced thrombocytopenia.

          -  Has a history of alcohol abuse or dependence within 12 months prior to the study.

          -  Has a positive alcohol test at screening or baseline and/or is unwilling to abstain
             from alcohol for 72 hours prior to the start of dosing until discharged from the
             clinic and for 72 hours prior to the follow-up visit.

          -  Is unwilling to abstain from caffeine- or xanthine-containing products for 24 hours
             prior to each dose and throughout each in-house period, and for 24 hours prior to the
             follow-up visit.

          -  The subject smokes or has used tobacco or nicotine-containing products within the 6
             months prior to the study, or is positive for urine cotinine at screening or at
             baseline.

          -  Is unwilling to refrain from the use of tobacco or illicit drugs during the trial,
             and/or tests positive for urine cotinine or drugs of abuse at screening or at
             baseline. At minimum, the list of drugs or classes of drugs that will be screened for
             include the following: amphetamines, barbiturates, benzoylecgonine, benzodiazepines,
             cannabinoids, cotinine, and opiates.

          -  Where participation in the study would result in donation of blood in excess of 500 ml
             within a 56 day period.

          -  Has a systolic blood pressure outside the range of 140 to 90mmHg, a diastolic blood
             pressure outside the range of 90 to 60mmHg and/or a heart rate outside the range of 90
             to 45bpm, inclusive, at screening or at baseline.

          -  Experiencing clinically significant ECG abnormalities at screening or at baseline.

          -  Has a history or current evidence of a positive HIV test.

          -  Has a history of or a positive pre-study Hepatitis B surface antigen or positive
             Hepatitis C antibody result within 3 months of screening.

          -  Has laboratory safety screening tests outside of ranges specified in the protocol at
             screening or at baseline. T.

          -  Pregnant or lactating women, or woman of childbearing potential.

          -  Has a history of rhabdomyolysis.

          -  Has congestive heart failure or a history of congestive heart failure with New York
             Heart Association Class I-IV symptoms

          -  Has a history of thyroid dysfunction or an abnormal thyroid function test as assessed
             by TSH at screening.

          -  Has a history or current evidence of sleep apnea.

          -  Has had previous exposure to GSK376501, with the exception of subjects randomized into
             a previously completed study with GSK376501 may participate only in the cohort
             evaluating pioglitazone.

          -  Has had treatment with any other new molecular entity (investigational drug) during
             the previous 30 days or 5 half-lives, or twice the duration of the biological effect
             of the drug (whichever is longer), prior to the first dose of current study
             medication. For the purposes of this study, a new molecular entity is defined as any
             compound that has not yet reached Phase 3 development. The washout is defined from
             last dose of study medication in the previous study until the first dose of study
             drug.

          -  Has been exposed to more than four new molecular entities within 12 months prior to
             the first dosing day.

          -  Has used the following prescription or non-prescription medications within 14 days or
             5 half lives, whichever is longer, prior to the first dose of study medication:
             vitamins (at a dose greater than the recommended daily allowance), or dietary or
             herbal supplements, including St. John's Wort.

          -  Is unable or unwilling to discontinue use of acetaminophen 72 hours prior to each dose
             and throughout each in-house period and no use within 72 hours of the follow-up visit.

          -  Requires the use of a prohibited medication .

          -  Is unable or unwilling to abstain from the consumption of grapefruit or grapefruit
             juice for 7 days prior to the first dose of study medication until the final
             pharmacokinetic sample has been collected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 15, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>GSK376501,</keyword>
  <keyword>Single Dose,</keyword>
  <keyword>Dose Escalation,</keyword>
  <keyword>Healthy Overweight/Obese Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

